We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A role for coagulation factor Xa in experimental pulmonary arterial hypertension.
- Authors
Delbeck, Martina; Nickel, Katrin F; Perzborn, Elisabeth; Ellinghaus, Peter; Strassburger, Julia; Kast, Raimund; Laux, Volker; Schäfer, Stefan; Schermuly, Ralph T; von Degenfeld, Georges
- Abstract
Anticoagulation with warfarin is recommended for the treatment of patients with pulmonary arterial hypertension (PAH). However, the therapeutic benefit of anticoagulation has not yet been demonstrated experimentally or clinically. Here, rivaroxaban, an oral, direct factor Xa (FXa) inhibitor, was compared with warfarin and enoxaparin in the prevention of right ventricular (RV) dysfunction and hypertrophy in the monocrotaline (MCT) model of pulmonary hypertension.
- Publication
Cardiovascular research, 2011, Vol 92, Issue 1, p159
- ISSN
1755-3245
- Publication type
Journal Article
- DOI
10.1093/cvr/cvr168